According to a recent LinkedIn post from Kardigan, the company is accepting applications for its 2026 Summer Internship Program focused on cardiovascular disease drug development. The post indicates that roles are open to undergraduate, MBA, and Ph.D. students and emphasize hands-on project work tied to cutting-edge science.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Kardigan is investing in early‑career talent as part of its long-term R&D capacity building. For investors, this focus on internships may signal an expanding research pipeline and efforts to strengthen future hiring funnels in a competitive biotech labor market, which could support the company’s innovation pace and potential asset development over time.